Clinical trials: Acute Myelogenous Leukemia (AML) Due to Therapy
Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes
CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
This is a phase 2 single-arm, open-label clinical trial determining efficacy of CPX-351 in combination with Glasdegib in subjects with Acute Myelogenous Leukemia with myelodysplastic syndrome related changes or therapy-related…
- Trial name
- NCT04231851
- Testing
- Glasdegib, CPX-351
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of California, Irvine